SYNCHRONIZE-1: Survodutide Phase 3 Obesity Results Explained

Survodutide produced a mean weight change of -12.2% on the 3.6 mg dose and -13.0% on the 6.0 mg dose at 76 weeks in SYNCHRONIZE-1, against -5.4% on placebo, in 725 adults with obesity or overweight and no diabetes ^[1]. Those are the figures in the New England Journal of Medicine report. The 16.6% figure in many headlines comes from a different analysis, one the manufacturer describes as assuming patients stayed on treatment for the whole study ^[3].

What the trial tested

SYNCHRONIZE-1 was a double-blind phase 3 trial. Adults with a BMI of 30 or higher, or 27 or higher with at least one obesity-related complication other than diabetes, were randomized 1:1:1 to weekly subcutaneous survodutide adjusted up to 3.6 mg, survodutide adjusted up to 6.0 mg, or placebo, all with lifestyle counseling ^[1]. The two primary endpoints were percent change in body weight and the share of people losing at least 5%, both measured at week 76 ^[1]. The published design paper notes that dose flexibility was permitted, so the arm labels describe the target dose ^[5].

Participants averaged 47.1 years of age, a BMI of 37.9 and 108.8 kg at baseline, and 40.6% were men ^[1]. They came from 14 countries, with 47.3% from North America, 21.0% from Europe and 20.0% from East Asia ^[2]. Hypertension was reported in 40.0%, dyslipidemia in 33.7% and prediabetes in 30.2% ^[2].

The published results

Every comparison with placebo on the two primary endpoints was statistically significant (P<0.001) ^[1]. The table below reproduces the NEJM abstract’s treatment-regimen results ^[1].

Subtracting placebo, which is our arithmetic and not a figure from the abstract, leaves a gap of about 6.8 percentage points on 3.6 mg and 7.6 on 6.0 mg ^[1]. The two doses sit close together, and their confidence intervals overlap ^[1]. The abstract tests each dose against placebo and does not report a comparison between doses, so it cannot tell us the higher dose adds nothing. It does show gastrointestinal events running higher on 6.0 mg, at 89.7% versus 80.9% ^[1].

Why you see both 13% and 16.6%

The two numbers answer different questions. Per the NEJM abstract, the treatment-regimen estimand “incorporates the effects of any early discontinuation of survodutide or placebo, the use of protocol-prohibited obesity medications, and a prolonged dose-escalation period” ^[1]. It estimates what happens when a group of people is offered the drug, including those who stop.

The efficacy estimand asks what would happen if everyone stayed on treatment. On that basis Boehringer Ingelheim reported weight loss of up to an average of 16.6%, versus 3.2% on placebo ^[3], and trade coverage of the April 2026 topline announcement gave up to 85.1% reaching at least 5% loss, versus 38.8% on placebo ^[4]. The company’s own footnote calls the efficacy p-values nominal, “calculated primarily for descriptive exploration” ^[3].

The placebo figure moves as well, from -3.2% to -5.4% ^[1][3]. So the placebo-subtracted gap is about 13.4 points under one analysis and 7.6 under the other, again by our subtraction. The treatment-regimen analysis counts protocol-prohibited obesity medications ^[1], and the abstract does not say how much of the placebo group’s result that explains. Neither number is wrong. A patient deciding whether a drug is worth starting should give weight to the treatment-regimen result, since real people do stop medications, and should read any higher figure as the best case for those who stay on it.

How it compares with phase 2

The phase 2 dose-finding trial ran 46 weeks in 386 treated adults without diabetes. Under its planned-treatment primary analysis, the 4.8 mg dose produced -14.9% versus -2.8% on placebo, and only 60.4% of participants completed treatment ^[6]. A 2026 review quotes the same dose at up to 18.7% versus 2.3% ^[7]. Phase 2 headlines and phase 3 results should not be lined up without checking which analysis each one uses.

Next to semaglutide and tirzepatide

No trial in this article compares survodutide directly with an approved drug, so this table is context and not a ranking. STEP 1 tested semaglutide 2.4 mg ^[8] and SURMOUNT-1 tested tirzepatide ^[9]. Each trial’s abstract reports an estimand that counts people regardless of discontinuation, and each enrolled adults without diabetes, but the durations, populations and placebo results differ ^[1][8][9].

The size of the placebo response is the first thing to notice. A 5.4% loss on placebo over 76 weeks is well above the 2.4% and 3.1% seen in the other two trials ^[1][8][9], and the published abstract does not explain why. Within the glucagon class, a 2026 network meta-analysis of 14 randomized trials in people with type 2 diabetes, overweight or obesity ranked retatrutide first for weight reduction versus placebo (-13.44 kg), followed by survodutide (-10.74 kg) and mazdutide (-6.47 kg) ^[13]. That estimate is indirect and drew on trials the authors describe as early and mid-phase ^[13].

Side effects and what is not yet known

Gastrointestinal symptoms were the most common adverse events and were described as typically mild to moderate, and no deaths were reported ^[1]. The abstract does not give rates of nausea, vomiting or diarrhea individually, so we do not quote them here. The company’s release reports that 19% of people on survodutide stopped treatment because of gastrointestinal adverse events, versus 2.9% on placebo ^[3]. In phase 2, gastrointestinal events affected 75% of survodutide recipients and 42% of those on placebo ^[6].

A review published in 2026 lists what remains to be established: comparative effectiveness, durability, long-term safety, treatment persistence and effects after discontinuation ^[7]. SYNCHRONIZE-1’s 76-week primary readout does not settle those. The cardiovascular question sits with SYNCHRONIZE-CVOT, an event-driven trial with a target of 4,935 participants and a five-point major adverse cardiovascular event endpoint ^[12].

Fat, liver and the rest of the program

The company reports that an MRI substudy of SYNCHRONIZE-1 showed relative reductions of up to 34.0% in visceral fat and up to 63.1% in liver fat, with lean mass accounting for no more than 10.8% of the change in total tissue mass at the highest dose ^[3]. These come from a press release, cover only participants with MRI measurements at baseline and end of study while on treatment, and carry no placebo comparison in that text, so treat them as preliminary ^[3].

• SYNCHRONIZE-2 (obesity with type 2 diabetes): 752 participants, -8.2% on 3.6 mg and -9.8% on 6.0 mg versus -3.9% on placebo at week 76. HbA1c, from a baseline of 7.4%, changed by -0.9, -0.8 and -0.2 percentage points respectively ^[10].
• SYNCHRONIZE-MASLD (obesity with at-risk fatty liver disease): 216 adults on 6.0 mg or placebo for 48 weeks. Under the treatment-regimen estimand, 68.5% versus 28.6% had at least a 30% reduction in liver fat, and weight changed -8.7% versus -1.4% ^[11]. The authors flag the short duration and recruitment limited to the United States and Spain ^[11].

For where survodutide sits among other late-stage compounds, our pipeline roundup covers MariTide and ecnoglutide alongside it.

What this means for a patient

Boehringer Ingelheim’s June 2026 release described survodutide as “an investigational agent” that “has not been approved for use” ^[3]. The trial doses are research doses, and they are not instructions anyone can follow. Because survodutide is not approved, nothing sold online under this name can be assumed to be the product these trials studied. If the results raise questions for you, useful ones for a prescriber are which approved medication fits your health history, what weight change to expect if you stay on it versus stop, and how gastrointestinal side effects would be managed.